Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

NGS-Assisted DNA-Based Digital qPCR Facilitates Stratification Of CML Patients In Long-Term Molecular Remission Based On The Presence Of Detectable BCR-ABL1 DNA

Mary Alikian, Peter Ellery, Matrin Forbes, Gareth Gerrard, PhD, Tim Aitman, Dalia Kasperaviciute, Dragana Milojkovic, PhD, David Marin, MD, John M Goldman, MD, Jane F Apperley, MD, Letizia Foroni, MD, Alistair Reid, PhD

Blood (2013) 122 (21): 4006.

https://doi.org/10.1182/blood.V122.21.4006.4006

Published: 2013

Journal Articles

Clinical Drug Resistance Linked to Inter-Convertible Phenotypic and Functional States of Tumor-Propagating Cells in Multiple Myeloma.

Blood (2012) 120 (21): 2909.

https://doi.org/10.1182/blood.V120.21.2909.2909

Published: 2012

Journal Articles

Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.

Frederick Pimm, Richard Szydlo, PhD, Letizia Foroni, Francesco Dazzi, MD, Jaspal S Kaeda, PhD, Gareth Gerrard, PhD, Alistair Reid, PhD, Mikel Valganon, BSc, Edward J Kanfer, John M Goldman, MD, Dragana Milojkovic, David Marin, Jane Apperley

Blood (2012) 120 (21): 2789.

https://doi.org/10.1182/blood.V120.21.2789.2789

Published: 2012

Journal Articles

Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?

Pratap Neelakantan, MRCP, Dragana Milojkovic, Gareth Gerrard, PhD, Letizia Foroni, Jane Apperley, Richard M Szydlo, Alistair Reid, PhD, Marco Bua, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, MD, David Marin

Blood (2012) 120 (21): 3760.

https://doi.org/10.1182/blood.V120.21.3760.3760

Published: 2012

Journal Articles

PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients

Juan M. Alonso-Dominguez, Sr., MD, Jacob Grinfeld, MD, Mary Alikian, David Marin, Alistair Reid, PhD, Mustafa Daghistani, Jane Apperley, John M Goldman, MD, Corinne Hedgley, Steve O‘Brien, Richard E. Clark, MD, Letizia Foroni, Gareth Gerrard, PhD

Blood (2012) 120 (21): 875.

https://doi.org/10.1182/blood.V120.21.875.875

Published: 2012

Journal Articles

Contrasting Effects of Enhanced Sirt1 Activity in Normal and BCR-ABL1-Depedent Haematopoiesis

Ming Hu, PhD, Jamshid S Khorashad, MD, PhD, Aristeidis Chaidos, MD, PhD, Georgios Nteliopoulos, PhD, Mattaka Khongkow, Ms, Irene Roberts, John Goldman, DM, FRCP, FRCPath, FMedSci, Alistair Reid, PhD, Eric W-.F. Lam, PhD, Jane Apperley, Anastasios Karadimitris, MD, PhD

Blood (2012) 120 (21): 1215.

https://doi.org/10.1182/blood.V120.21.1215.1215

Published: 2012

Journal Articles

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

Dragana Milojkovic, MD, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Amr R Ibrahim, Marco Bua, MD, Alistair Reid, PhD, Gareth Gerrard, PhD, Letizia Foroni, MD PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 3777.

https://doi.org/10.1182/blood.V118.21.3777.3777

Published: 2011

Journal Articles

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Dragana Milojkovic, MD, Gareth Gerrard, PhD, Christos Paliompeis, Marco Bua, MD, Alistair Reid, PhD, Mary Alikian, Jamshid Khorashad, MD, PhD, John M Goldman, David Marin, Letizia Foroni, MD PhD, Jane F Apperley, MBChB, MD, FRCP, FRCPath

Blood (2011) 118 (21): 605.

https://doi.org/10.1182/blood.V118.21.605.605

Published: 2011

Journal Articles

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Dragana Milojkovic, MD, Amr R Ibrahim, Letizia Foroni, MD PhD, Claire Lucas, Gareth Gerrard, PhD, Lihui Wang, Richard M Szydlo, Richard E Clark, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Marco Bua, MD, Jiri Pavlu, Christos Paliompeis, Alistair Reid, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 1680.

https://doi.org/10.1182/blood.V118.21.1680.1680

Published: 2011

Journal Articles

Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.

Hugues de Lavallade, MD, Dragana Milojkovic, MD, Jamshid S. Khorashad, MD, Alistair Reid, PhD, Eduardo Olavarria, MD, Jaspal Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 1045.

https://doi.org/10.1182/blood.V110.11.1045.1045

Published: 2007

Journal Articles

Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.

Hugues de Lavallade, MD, Jamshid S. Khorashad, MD, Marco Bua, MD, Dragana Milojkovic, MD, Eduardo Olavarria, MD, Alistair Reid, PhD, Jaspal S. Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 1037.

https://doi.org/10.1182/blood.V110.11.1037.1037

Published: 2007

Journal Articles

Philadelphia Negative BCR/ABL1 Positive CML: FISH Mapping and aCGH Reveal Breakpoint Hotspots.

Anna Virgili, Diana Brazma, MD, Colin Grace, PhD, Anastasios Chanalaris, PhD, Alistair Reid, PhD, Jane F. Apperley, MD, PhD, Elisabeth P. Nacheva, MD, PhD

Blood (2007) 110 (11): 2924.

https://doi.org/10.1182/blood.V110.11.2924.2924

Published: 2007

NARROW

NGS-Assisted DNA-Based Digital qPCR Facilitates Stratification Of CML Patients In Long-Term Molecular Remission Based On The Presence Of Detectable BCR-ABL1 DNA

Clinical Drug Resistance Linked to Inter-Convertible Phenotypic and Functional States of Tumor-Propagating Cells in Multiple Myeloma.

Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.

Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?

PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients

Contrasting Effects of Enhanced Sirt1 Activity in Normal and BCR-ABL1-Depedent Haematopoiesis

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.

Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.

Philadelphia Negative BCR/ABL1 Positive CML: FISH Mapping and aCGH Reveal Breakpoint Hotspots.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only